Healthcare
PTC Therapeutics, Inc.(PTCT)
Live Price
Offline$78.98
+0.57% today
1Y Change
+59.23%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $5.40B
- Revenue Growth
- +114.5%
- EPS Growth
- +281.4%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PTC Therapeutics, Inc. (PTCT) is a Healthcare stock with a market cap of $5.40B and listed on NASDAQ. The stock last traded around $78.98 and up 59.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +114.5%, EPS growth of +281.4%, a dividend yield of 0.0%. What stands out right now is revenue +114.5%, EPS +281.4%, free cash flow +486.0% with operating margin 49.5% and ROIC 37.4%. Valuation is more restrained than many high-expectation growth names at P/E 7.7 and price/sales 3.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PTCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+114.5% vs +7.6% peer median
Operating Margin
Above sector median
+49.5% vs +19.4% peer median
P/E
Below sector median
7.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +114.5% and EPS at +281.4%, with operating margin around 49.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +2.4% | +15.3% | +5.6% |
2026 Feb 19, 2026 | -695.2% | +1.1% | -2.6% | -4.0% |
2025 Nov 4, 2025 | +116.8% | +6.0% | +9.0% | +11.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTCT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTCT Max Drawdown
-27.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTCT and SPY.
Company Overview
PTC Therapeutics, Inc.
NASDAQ Global Select
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
- Leadership
- Matthew Klein
- IPO Date
- Jun 20, 2013
- Employees
- 939
- Street Address
- 100 Corporate Court
- Mailing
- Warren, NJ, 07080
- Region
- Warren, NJ, US
- Reporting Currency
- USD
- Investor Line
- 908 222 7000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 7.7
- EV/EBITDA
- 5.5
- Price/Sales
- 3.1
- Price/Book
- โ
Growth
- Revenue
- +114.5%
- EPS
- +281.4%
- Free Cash Flow
- +486.0%
Profitability
- Gross Margin
- 91.0%
- Operating Margin
- 49.5%
- Net Margin
- 39.4%
- ROE
- -362.4%
- ROIC
- 37.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.